These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28539357)

  • 41. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
    Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
    Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Genetics of Clinical Liver Diseases: Insight into the
    Zhang X; Liu S; Dong Q; Xin Y; Xuan S
    J Clin Transl Hepatol; 2018 Sep; 6(3):326-331. PubMed ID: 30271746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
    Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
    J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.
    Oliveira AIN; Malta FM; Zitelli PMY; Salles APM; Gomes-Gouvea MS; Nastri ACS; Pinho JRR; Carrilho FJ; Oliveira CP; Mendes-Corrêa MC; Pessoa MG; Mazo DF
    BMC Gastroenterol; 2021 Feb; 21(1):81. PubMed ID: 33622266
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Research progress of single-nucleotide polymorphism in theTM6SF2 rs58542926].
    Li Y; Sun X; Zhan SH; Gao YQ; Xin YN; Xuan SY
    Zhonghua Gan Zang Bing Za Zhi; 2019 Mar; 27(3):223-226. PubMed ID: 30929342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
    Kruk B; Liebe R; Milkiewicz M; Wunsch E; Raszeja-Wyszomirska J; Lammert F; Milkiewicz P; Krawczyk M
    PLoS One; 2018; 13(8):e0202942. PubMed ID: 30161167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.
    Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Grandone A; Cirillo G; Salpietro S; Minichini C; Starace M; Messina E; Morelli P; Miraglia Del Giudice E; Lazzarin A; Coppola N; Sagnelli E
    World J Gastroenterol; 2016 Oct; 22(38):8509-8518. PubMed ID: 27784963
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease.
    Luo F; Oldoni F; Das A
    Hepatol Commun; 2022 Mar; 6(3):448-460. PubMed ID: 34532996
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
    Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
    Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
    Liu YL; Reeves HL; Burt AD; Tiniakos D; McPherson S; Leathart JB; Allison ME; Alexander GJ; Piguet AC; Anty R; Donaldson P; Aithal GP; Francque S; Van Gaal L; Clement K; Ratziu V; Dufour JF; Day CP; Daly AK; Anstee QM
    Nat Commun; 2014 Jun; 5():4309. PubMed ID: 24978903
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation.
    Míková I; Neřoldová M; Hubáček JA; Dlouhá D; Jirsa M; Honsová E; Sticová E; Lánská V; Špičák J; Trunečka P
    Transplantation; 2020 Mar; 104(3):526-534. PubMed ID: 31356578
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A study of genetic variants, genetic risk score and DNA methylation of PNPLA3 and TM6SF2 in alcohol liver cirrhosis.
    Shankarappa B; Mahadevan J; Murthy P; Purushottam M; Viswanath B; Jain S; Devarbhavi H; Mysore V A
    Indian J Gastroenterol; 2023 Dec; 42(6):800-807. PubMed ID: 37589914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.
    Smagris E; Gilyard S; BasuRay S; Cohen JC; Hobbs HH
    J Biol Chem; 2016 May; 291(20):10659-76. PubMed ID: 27013658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.
    Grandone A; Cozzolino D; Marzuillo P; Cirillo G; Di Sessa A; Ruggiero L; Di Palma MR; Perrone L; Miraglia Del Giudice E
    Pediatr Obes; 2016 Apr; 11(2):115-9. PubMed ID: 25893821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy.
    Taskinen MR; Matikainen N; Björnson E; Söderlund S; Inkeri J; Hakkarainen A; Parviainen H; Sihlbom C; Thorsell A; Andersson L; Adiels M; Packard CJ; Borén J
    Diabetologia; 2023 Dec; 66(12):2307-2319. PubMed ID: 37775612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study.
    Xia M; Ma S; Huang Q; Zeng H; Ge J; Xu W; Wu Q; Wu L; Li X; Ma H; Chen L; Li Q; Aleteng Q; Hu Y; He W; Pan B; Lin H; Zheng Y; Wang S; Tang H; Gao X
    Aliment Pharmacol Ther; 2022 Mar; 55(6):705-721. PubMed ID: 35023183
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis.
    Israelsen M; Juel HB; Detlefsen S; Madsen BS; Rasmussen DN; Larsen TR; Kjærgaard M; Fernandes Jensen MJ; Stender S; Hansen T; Krag A; Thiele M;
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1784-1794.e9. PubMed ID: 33279778
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Women produce fewer but triglyceride-richer very low-density lipoproteins than men.
    Magkos F; Patterson BW; Mohammed BS; Klein S; Mittendorfer B
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1311-8. PubMed ID: 17264179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.